Sign In
Buy NUVL
$90.18
-1.17 (-1.28%)
At Close: Jun 03, 2026
Why Nuvalent Stock Was Soaring Wednesday
04:13pm, Wednesday, 04'th Oct 2023
Nuvalent is a clinical-stage biotech. The company said its therapy showed effectiveness and a strong safety profile in its phase 1/2 trial to treat ALK-positive non-small cell lung cancer.
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
06:30am, Monday, 18'th Sep 2023
Company plans to host a conference call on October 13, 2023 CAMBRIDGE, Mass. , Sept. 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creat
Nuvalent to Participate in Upcoming September Investor Conferences
06:30am, Thursday, 31'st Aug 2023
CAMBRIDGE, Mass. , Aug. 31, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinas
Deerfield Management Company, L.P.
10:03pm, Tuesday, 01'st Aug 2023
Deerfield Management Company, L.P. (Series C), a renowned investment firm, recently made a significant addition to its portfolio.
Nuvalent to Participate in Upcoming August Investor Conferences
06:30am, Tuesday, 01'st Aug 2023
CAMBRIDGE, Mass. , Aug. 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase
Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why
09:57am, Friday, 21'st Jul 2023
If you are looking for stocks that are well positioned to maintain their recent uptrend, Nuvalent, Inc. (NUVL) could be a great choice. It is one of the several stocks that passed through our "Recent
Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why
10:03am, Wednesday, 07'th Jun 2023
Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
06:30am, Thursday, 23'rd Mar 2023
CAMBRIDGE, Mass. , March 23, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kin
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023
05:59pm, Tuesday, 14'th Mar 2023
CAMBRIDGE, Mass. , March 14, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kin
Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference
06:30am, Wednesday, 04'th Jan 2023
CAMBRIDGE, Mass. , Jan. 4, 2023 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kina
MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge
10:12am, Monday, 02'nd Jan 2023
Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining o
Nuvalent Looks Overvalued After A Rapid Rally
03:48pm, Wednesday, 14'th Dec 2022
Surprisingly, Nuvalent, Inc. has attracted a lot of market interest over the past year, while known headwinds have put the entire biotech sector under strong upward pressure. As a result, Nuvalent sto
Here's Why Momentum in Nuvalent, Inc. (NUVL) Should Keep going
10:32am, Friday, 02'nd Dec 2022
Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through
What Makes Nuvalent, Inc. (NUVL) a Strong Momentum Stock: Buy Now?
01:32pm, Thursday, 17'th Nov 2022
Does Nuvalent, Inc. (NUVL) have what it takes to be a top stock pick for momentum investors? Let's find out.
CAMBRIDGE, Mass. , Oct. 17, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kina
